Physician profile
Peter B Spencer
NPI 1669479432
$1,628.11
in general payments reported to CMS, 2019-2025
32 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $77.57 · 2021: $256 · 2022: $171 · 2023: $181 · 2024: $266 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.43 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Biogen, INC. | $93.53 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Sk Life Science, INC. | $84.60 | 2021-2024 | |
| Emd Serono, INC. | $76.01 | 2019-2025 | |
| Lilly USA, LLC | $60.69 | 2019-2025 | Kisunla, Amyvid |
| Janssen Pharmaceuticals, INC | $60.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $59.85 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $53.45 | 2019-2024 | Ajovy |
| Sunovion Pharmaceuticals INC. | $50.50 | 2020-2021 | |
| Genentech USA, INC. | $49.69 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Allergan, INC. | $41.28 | 2019-2022 | |
| Pfizer INC. | $41.14 | 2021-2025 | |
| Argenx US, INC. | $40.39 | 2023-2025 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $39.06 | 2019-2023 | |
| Ucb, INC. | $37.96 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $37.08 | 2022-2023 | Rytary |
| Janssen Biotech, INC. | $29.34 | 2025 | |
| Csl Behring | $26.58 | 2019-2020 | |
| Amgen INC. | $21.13 | 2019 | |
| Celgene Corporation | $20.59 | 2023 | Zeposia |
| Cycle Pharmaceuticals INC | $20.51 | 2025 | Bafiertam, Tascenso Odt |
| Neurocrine Biosciences, INC. | $19.38 | 2022 | |
| Aucta Pharmaceuticals, INC. | $19.20 | 2024 | Motpoly Xr |
| Eisai INC. | $19.05 | 2023 | |
| Boston Scientific Corporation | $18.15 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.98 | 2025 | Rexulti |
| Lundbeck LLC | $17.86 | 2021 | |
| Kyowa Kirin, INC. | $16.45 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.34 | 2019 | |
| Medtronic USA, INC. | $15.48 | 2019 | |
| Neurelis, INC. | $14.60 | 2021 | |
| Livanova USA, INC. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.